John Kulman
CSO Zag Bio
John D. Kulman, Ph.D. is an experienced drug developer with over 20 years of scientific leadership experience in academia and industry and a track record of advancing both first- and best-in-class biologics and gene editing therapies to the clinic and through to marketing approval, including Eloctate®, Alprolix®, Altuviiio®, and Casgevy®. Most recently, Dr. Kulman served on the executive leadership team at CRISPR Therapeutics where he led Discovery Research and Translational Genomics. Previously, he was the Head of Research at Codiak Biosciences, where he pioneered the development of engineered therapeutic exosomes. Prior to that he held positions of increasing scientific leadership at Biogen. He holds an M.Phil. in Biochemistry from the University of Cambridge and a Ph.D. in Biochemistry from the University of Washington.
Seminars
- Thymology 101: How the thymus shapes the T cell repertoire by induction of potent and durable Tregs and deletion of autoreactive Tconv cells
- Zag Bio’s biologics-based approach to target systemically administered antigens to the thymus for restoration of immune homeostasis
- Demonstration of tissue-specific bystander suppression in autoimmune disease models
